Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) is a clinical-stage biopharma leader developing novel cancer immunotherapies through its proprietary Boltbody ISAC platform. This page provides investors and researchers with essential updates on clinical trials, strategic collaborations, and therapeutic innovations in immuno-oncology.
Our curated news collection offers immediate access to official press releases and verified developments. Users can track progress across three key areas: clinical trial milestones for solid tumor treatments, research partnerships advancing myeloid-targeted therapies, and platform enhancements to the Boltbody ISAC technology.
All content undergoes rigorous verification to ensure compliance with financial disclosure standards. The resource is particularly valuable for monitoring BOLT's progress in activating both innate and adaptive immune responses through targeted antibody conjugates.
Bookmark this page for streamlined access to BOLT's evolving position in cancer immunotherapy. For comprehensive analysis of how these developments impact therapeutic pipelines and investment considerations, consult your financial advisor.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, has announced changes to its Board of Directors. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, has been appointed to the board, bringing over 20 years of experience in oncology and immuno-oncology. Concurrently, Dr. Jim Healy is stepping down as Lead Independent Director, Frank D. Lee is departing the board, and Brian O'Callaghan, CEO of Deep Genomics, will assume the role of Chair.
Dr. Dupont's extensive background includes leadership roles at Atara Biotherapeutics, Gossamer Bio, and Genentech/Roche, where he was instrumental in developing several successful cancer therapies. His appointment is expected to benefit Bolt's pipeline advancement and collaborations. The company is currently conducting a clinical trial with a first-in-class Dectin-2 agonist and has a near-clinical ISAC program targeting Claudin 18.2.
Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:
1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.
2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.
Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Advancement to cohort 6 in the Phase 1 study of BDC-3042 for advanced cancers.
2. Acceptance of an abstract for BDC-4182, a claudin 18.2-targeting Boltbody ISAC, at the SITC 39th Annual Meeting.
3. Cash balance of $97.5 million as of June 30, 2024, expected to fund operations through mid-2026.
4. Q2 2024 financial results: Collaboration revenue of $1.3 million, R&D expenses of $15.4 million, G&A expenses of $4.9 million, and a loss from operations of $22.6 million.
5. Ongoing collaborations with Genmab and Toray continue to progress.
Bolt Biotherapeutics (Nasdaq: BOLT) announced its Q1 2024 financial results, revealing a strategic pipeline prioritization and leadership changes. The company will focus on its Phase 1 Dectin-2 agonist antibody BDC-3042 and its next-gen Boltbody™ ISAC platform, including the new clinical candidate BDC-4182 targeting Claudin 18.2. Development of trastuzumab imbotolimod (BDC-1001) will halt, and the workforce will be cut by approximately 50% to extend the cash runway into the second half of 2026.
Willie Quinn replaces Randall Schatzman as CEO, with other leadership promotions announced. Financially, Bolt reported collaboration revenue of $5.3 million, up from $1.8 million in Q1 2023, and a loss from operations of $17.1 million, down from $18.4 million the previous year. R&D expenses increased to $16.5 million, driven by higher clinical trial costs. G&A expenses rose slightly to $5.8 million. The company will host a webcast to discuss these changes.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
